Sarcome Kaposi · ligne 2 · Paclitaxel en monothérapie (sarcome de Kaposi, post-anthracycline)

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

Contenu clinique provisoire : il ne s'agit pas d'une ordonnance. Un oncologue doit vérifier les sources originales, l'applicabilité et le statut de révision.

Source YAML: dossier complet

Ligne thérapeutique	2
Voie	standard
Régime lié	`REG-PACLITAXEL-KAPOSI`

ID	`IND-KAPOSI-2L-VISCERAL-PACLITAXEL`
Type	Indication
État	reviewed 2026-07-11 \| pending_clinical_signoff
Maladies	`DIS-KAPOSI`
Sources	`SRC-NCCN-SKIN-2025`

Notes

STUB -- new TREATMENT-intent 2L Indication for DIS-KAPOSI (v0.3 continuation). Introduces new Regimen REG-PACLITAXEL-KAPOSI (reuses the existing DRUG-PACLITAXEL entity). evidence_level set to `low` and strength_of_recommendation to `conditional` specifically because of the unresolved KS-specific dosing gap (see `rationale` and the Regimen's own `notes`) -- NOT because the FDA-approved-2L-status fact itself is uncertain. Not referenced from ALGO-KAPOSI-1L's output_indications (that Algorithm is explicitly scoped to 1L routing); reachable via IND-KAPOSI-1L-VISCERAL-PLD.followed_by. A dedicated 2L algorithm is out of scope for this authoring pass. INDEPENDENT REVIEW CORRECTION (2026-07-11): an earlier draft cited SRC-NCCN-SKIN-2025 with position "supports". That source documents only basal-cell/squamous-cell skin cancer (confirmed by direct inspection of its own KB record), not Kaposi sarcoma -- downgraded to "context". The FDA-2L-approval fact is independently supported by the already-verified DRUG-PACLITAXEL entity, not by this citation. Pending two-Clinical-Co-Lead signoff (CHARTER §6.1 -- dev-mode- exempted; safe to merge as draft content, NOT as published/verified clinical advic...

Utilisé par

Algorithmes

ALGO-KAPOSI-1L - ALGO-KAPOSI-1L

Maladie

DIS-KAPOSI - Sarcome Kaposi

Indication

IND-KAPOSI-1L-VISCERAL-PLD - IND-KAPOSI-1L-VISCERAL-PLD